AI-generated summary
The authors report a randomised phase II trial of laser photobiomodulation versus sham control in 44 cancer survivors with established chemotherapy-induced peripheral neuropathy. Patient-reported symptoms improved in both groups after the intervention, and the authors state that improvement in the laser group was sustained at 12 weeks, though they note a larger study is needed.
- Participants
- 44
- Who or what was studied
- Cancer survivors reporting chemotherapy-induced peripheral neuropathy symptoms at least 3 months after completing neurotoxic chemotherapy
- Limits stated in the abstract
- The authors state a larger study is warranted, and the trial was single-blinded and non-comparative with a modest sample of 44 participants.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Photobiomodulation, Neuropathy, Sham, Primary outcome, Control group, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.